As shown in Figure 5a, selinexor (9) was FDA-approved in 2019 for treating lymphomas and leukemia by covalently inhibiting the highly activated nuclear export receptor, exportin 1 (XPO1) [16]. This evidence concerns the gene XPO1 and lymphoma.